Back to results
US 12,742,018 B2Granted
Subcutaneous formulations of daratumumab and their uses in treating multiple myeloma
AssigneeJanssen Biotech, Inc.
InventorsRichard Jansson, Vineet Kumar
Life of this patent
Estimating the term…
Abstract
The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.
Claims30
A method of treating multiple myeloma in a subject, comprising subcutaneously administering to the subject a pharmaceutical composition comprising:
- a) daratumumab at a concentration of about 120 mg/mL, and
- b) rHuPH20 recombinant hyaluronidase,
- wherein the pharmaceutical composition has a total volume of about 15 mL and has a hyaluronidase enzymatic activity of about 2000 U/mL.
Dependencies are inferred from the claim text.